lung cancer News & Analysis
2 articles
Market Mood
Nanobiotix (NBTXR3) Lung Cancer Trial Data Presented at ESTRO
Nanobiotix (NBTXR3) presented early data from its lung cancer clinical trial at ESTRO. The presentation included initial results, highlighting a specific treatment's potential effectiveness in target populations. While specific quantitative results were not disclosed, the data could influence investor sentiment and expectations regarding upcoming FDA approvals. This event is significant for NBTXR3 as it may impact the company's market position and future funding opportunities in oncology.
Read More
Erasca (ERAS) Stock Recommended for Purchase by JPMorgan
Erasca, Inc. (ERAS) received an Overweight rating from JPMorgan, which recommends buying the stock at current levels due to anticipated catalysts. H.C. Wainwright also maintains a Buy rating with a price target of $20, following preliminary Phase 1 data for ERAS-0015, which shows potential efficacy in treating non-small cell lung cancer. The data indicates a clear increase in early efficacy, though the safety profile is noted to have some caveats. As a clinical-stage precision oncology company, Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.
Read More